Back Back

Mineralocorticoid Receptor Antagonists: Addressing Residual Risk in Patients with Cardiac Disease, T2DM, and CKD

T2DM is the leading cause of CKD worldwide and CVD is the leading cause of morbidity and mortality for patients with T2DM and for patients with CKD. People with T2DM and CKD are at increased risk for CVD and CV death compared with those with T2DM alone. Even with optimal medical therapy, these patients remain at high risk for CVD events and progression to ESRD. MRAs are recommended for the treatment of resistant HTN and for managing HF in patients with T2DM and CKD. Lack of guidelines for the use of MRAs and fear of hyperkalemia has resulted in many eeligible patients not being given MRAs, receiving them late in disease course, and/or are not receiving optimal dosing. New nonsteroidal MRAs are associated with a lower incidence of hyperkalemia and improved CKD and CVD benefits.

Share

Program Content

Activities

  • Addressing Residual Risk in Patients with Cardiac Disease, T2DM, and CKD
    Mineralocorticoid Receptor Antagonists: Addressing Residual Risk in Patients with Cardiac Disease, T2DM, and CKD
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2022

    Expires: December 20, 2023

    View Activity

Faculty

cover img faculity

Erin Michos, MD, MHS, FAHA, FACC, FASE, FASPC

Associate Professor of Medicine and Epidemiology
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Heart Disease
Division of Cardiology, Johns Hopkins School of Medicine
Baltimore, MD

cover img faculity

Muthiah Vaduganathan, MD, MPH

Co-Director, Center for Cardiometabolic Implementation Science
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

Provided by

ProCE Banner
ProCE Banner

Jointly provided by the Potomac Center for Medical Education and Rockpointe.

Supporters

This program is supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc.

Bayer HealthCare Pharmaceuticals Inc.